Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis
Background To eliminate cervical cancer as a public health problem, the World Health
Organization had recommended routine vaccination of adolescent girls with two doses of the …
Organization had recommended routine vaccination of adolescent girls with two doses of the …
Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review
Introduction The World Health Organization (WHO) recommends that human papillomavirus
(HPV) vaccination programs are established to be cost-effective before implementation …
(HPV) vaccination programs are established to be cost-effective before implementation …
Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a …
Background First generation bivalent and quadrivalent human papillomavirus (HPV)
vaccines have been introduced in most developed countries. A next generation nonavalent …
vaccines have been introduced in most developed countries. A next generation nonavalent …
Prevalence of HPV infection among HIV‑positive and HIV‑negative women in Central/Eastern Italy: Strategies of prevention
E Tartaglia, K Falasca, J Vecchiet… - Oncology …, 2017 - spandidos-publications.com
The present cross‑sectional‑study aimed to determine the prevalence of human
papillomavirus (HPV)‑genotypes among human immunodeficiency virus (HIV)‑positive and …
papillomavirus (HPV)‑genotypes among human immunodeficiency virus (HIV)‑positive and …
Cost-effectiveness of HPV vaccination for adults through age 45 years in the United States: Estimates from a simplified transmission model
HW Chesson, E Meites, DU Ekwueme, M Saraiya… - Vaccine, 2020 - Elsevier
Introduction The objective of this study was to assess incremental costs and benefits of a
human papillomavirus (HPV) vaccination program expanded to include “mid-adults”(adults …
human papillomavirus (HPV) vaccination program expanded to include “mid-adults”(adults …
[HTML][HTML] The nonavalent vaccine: a review of high-risk HPVs and a plea to the CDC
A Yusupov, D Popovsky, L Mahmood… - American journal of …, 2019 - ncbi.nlm.nih.gov
Two of the leading strategies to prevent cervical cancer are prophylactic human
papillomavirus (HPV) vaccination and routine Papanicolaou (Pap) testing. However …
papillomavirus (HPV) vaccination and routine Papanicolaou (Pap) testing. However …
Accounting for adverse events following immunization in economic evaluation: systematic review of economic evaluations of pediatric vaccines against …
K Doggen, AJ van Hoek, J Luyten - PharmacoEconomics, 2023 - Springer
Objectives Economic evaluations of vaccines should accurately represent all relevant
economic and health consequences of vaccination, including losses due to adverse events …
economic and health consequences of vaccination, including losses due to adverse events …
Cost-effectiveness of nonavalent HPV vaccination among males aged 22 through 26 years in the United States
HW Chesson, E Meites, DU Ekwueme, M Saraiya… - Vaccine, 2018 - Elsevier
Abstract Introduction In the United States, routine human papillomavirus (HPV) vaccination
is recommended for females and males at age 11 or 12 years; the series can be started at …
is recommended for females and males at age 11 or 12 years; the series can be started at …
Computational modeling of human papillomavirus with impulsive vaccination
HW Berhe, M Al-arydah - Nonlinear Dynamics, 2021 - Springer
In this study, a new SIVS epidemic model for human papillomavirus (HPV) is proposed. The
global dynamics of the proposed model are analyzed under pulse vaccination for the …
global dynamics of the proposed model are analyzed under pulse vaccination for the …
Simultaneously characterizing the comparative economics of routine female adolescent nonavalent human papillomavirus (HPV) vaccination and assortativity of …
Background Although routine vaccination of females before sexual debut against human
papillomavirus (HPV) has been found to be cost-effective around the world, its cost-benefit …
papillomavirus (HPV) has been found to be cost-effective around the world, its cost-benefit …